Our Story
Ksilink is a deeptech developing a pipeline of in house patient-based drug discovery programs and supporting customers with innovative solutions for advanced biomedical research & screening needs.
What we do
Leveraging our network of academia, industry, patients’ organizations, and clusters, we are bridging academic and industrial forces to address diseases where no other therapeutic approaches have proven effective or ever existed.
Our business model
We develop a pipeline of patient-based drug discovery programs in neurological disorders. We develop them as proprietary programs up to novel hit series or preclinical candidates to be further developed by the pharmaceutical industry.
We also have several projects in the cardiovascular indication space ongoing in collaborative partnerships.
Our differentiating features
-
We develop and exploit complex patient-based disease models for drug discovery supported by AI.
-
We believe that our approach will lead to drug candidates that are derisked because of their origin in patient derived cellular models.
Our why
-
Discovering new drugs solving today’s unmet medical need.
-
Advancing science by making outstanding expertise available
-
Achieving great outcomes faster by building precision networks in academia, biotech and pharmaceutical industry.
LAUNCH
Derisking innovation with public funding as Ksilink Association
The project is launched and set up, thanks to strong impulse from Inserm and Sanofi, and 16m€ funding from French Programme d’Investissement d’Avenir (PIA).
ACCELERATION
Moving Ksilink to the next step
Ksilink recruits own staff and invest into a tailored fully-automated sterile screening platform.
EXPLOITATION
Incorporation of Ksilink SAS
The technology platform and the team are transferred to a spin-off in the form of a limited company (SAS) to exploit generated results and drive pipeline to valuable endpoints for the industry.